Search clinical trials for: Rivaroxaban, (BAY59-7939)

Total 545 results

Assistance Publique - Hôpitaux de Paris
Bayer

Completed

Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban (CASTA-DIVA)

Venous Thromboembolism | Neoplasm

France
Fundació Institut de Recerca de l'Hospital de la...

Completed

Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance (HERO)

Ischemic Stroke

Spain, Italy
Portola Pharmaceuticals

Completed

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

Bleeding

United States
Nanfang Hospital, Southern Medical University

Recruiting

Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients

Glioma, Malignant

China
Armed Forces Post Graduate Medical Institute (AFPGMI)...

Recruiting

Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease

PAD - Peripheral Arterial Disease | Combined Anticoagulation and Antithrombotic Therapy

Pakistan
University Hospital Inselspital, Berne
Centre Hospitalier Universitaire Vaudois

Recruiting

Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis

Liver Cirrhosis

Switzerland
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF (APERITIF)

Myocardial Infarction, Acute | Left Ventricular Thrombus

France
Pharmtechnology LLC
ClinPharmInvest, LLC

Unknown

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions

Bioequivalence

Russian Federation
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Direct Oral Anticoagulants and Venous Thromboembolism

Venous Thromboembolism | Major Bleed

Canada
Janssen Scientific Affairs, LLC
Bayer

Completed

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy (VENTURE-AF)

Atrial Fibrillation

United States, France, United Kingdom, Belgium, Germany
VarmX B.V.

Recruiting

Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant

Coagulation Disorder

Netherlands
Cardioangiologisches Centrum Bethanien

Active, not recruiting

Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants

Heavy Menstrual Bleeding

Germany
Janssen Scientific Affairs, LLC
Bayer

Completed

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (PIONEER AF-PCI)

Atrial Fibrillation | Percutaneous Coronary Intervention

United States, France, Poland, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Argentina, Mexico, Bulgaria, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic of, Australia, Canada, Netherlands, Denmark and more
Herlev and Gentofte Hospital
Danish Society of Cardiology

Recruiting

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation (DANNOAC-AF)

Atrial Fibrillation | Atrial Flutter

Denmark
LEO Pharma
Bayer

Completed

Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

Papulopustular Rosacea

United States
St. Paul's Hospital, Canada

Active, not recruiting

The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery

Atrial Fibrillation

Canada
Yaounde Central Hospital

Unknown

Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19 (DOXYCOV)

COVID-19

Cameroon
Onze Lieve Vrouw Hospital

Completed

Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients

Vascular Calcification

Belgium
University of Colorado, Denver
Janssen Research & Development, LLC

Recruiting

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Lung Cancer | Non Small Cell Lung Cancer

United States
University Hospital, Angers

Not yet recruiting

RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing (RIVACAST)

Deep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism | Thromboprophylaxis | Lower Limb Trauma | Immobilisation

France
Peshawar Institute of Cardiology
Getz Pharma

Recruiting

Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial (WRAP)

Left Ventricular Thrombus

Pakistan
Science Valley Research Institute
Bayer

Completed

Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients

Intermittent Claudication | Peripheral Artery Disease

Brazil
Bristol-Myers Squibb

Completed

APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

Anticoagulation

France
The First Affiliated Hospital of Xiamen University

Recruiting

68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG

Positron-Emission Tomography | FAP | SSTR2

China
Janssen Research & Development, LLC
Harvard Medical School (HMS and HSDM); Bayer; Duke Clinical Research Institute

Completed

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome (GEMINI ACS 1)

Acute Coronary Syndrome

United States, France, Poland, Ukraine, Belgium, Spain, Argentina, Bulgaria, Russian Federation, Turkey, Japan, Canada, Netherlands, Korea, Republic of, Brazil, Australia, Hungary, Sweden, Czechia, Denmark
HK inno.N Corporation

Completed

PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers

Healthy

Korea, Republic of
Mayo Clinic

Withdrawn

FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients

Cardiac Disease
Pfizer

Completed

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

Carcinoma, Metastatic Breast

United States
Bayer

Completed

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

Hemophilia A

United States
Jung-min Ahn

Recruiting

Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement (RENOVATE)

Thromboembolism | AORTIC VALVE DISEASES

Korea, Republic of
Bayer

Completed

Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care (BEST-AF)

Atrial Fibrillation

United Kingdom
LEO Pharma
Bayer

Completed

Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne

Acne Vulgaris

United States
Population Health Research Institute

Completed

Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease

Ischemic Stroke | Intracranial Atherosclerotic Disease

Canada
Gilberto Cruz Arteaga
Coordinación de Investigación en Salud, Mexico

Completed

Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment

Covid19

Mexico
University Hospital, Tours

Not yet recruiting

Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients (CARD-AXA)

Chronic Hemodialysis Patients
Mayo Clinic
Ottawa Heart Institute Research Corporation

Recruiting

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)

Radial Artery Occlusion

United States
LiuZhou People's Hospital

Unknown

Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports

Cancer | Rivaroxaban | Thromboprophylaxis
Medical College of Wisconsin
Ohio State University; Versiti

Completed

Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis

Neoplasms | Venous Thrombosis

United States
Brazilian Clinical Research Institute
Hospital Israelita Albert Einstein; Hospital Moinhos de Vento; Hospital do Coracao and other collaborators

Completed

Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial (ACTION)

Coronavirus Infection

Brazil
J.P.S Henriques

Not yet recruiting

Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention (IMPACT AF-PCI)

Coronary Artery Disease | Atrial Fibrillation
Shanghai Zhongshan Hospital

Recruiting

Prophylactic vs Therapeutic Anticoagulation in Symptomatic Isolated Distal Deep Vein Thrombosis

Venous Thrombosis

China
Second Affiliated Hospital, School of Medicine,...
Bayer; The Central Hospital of Lishui City; Shaoxing People's Hospital; Wenzhou... and other collaborators

Recruiting

Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban

Intracranial Hemorrhages | Anticoagulant | Cerebrovascular Stroke | Matrix Metalloproteinases

China
China-Japan Friendship Hospital

Not yet recruiting

Effectiveness and Safety of Rivaroxaban Used in Extended Anticoagulation for Pulmonary Embolism Patients

Pulmonary Embolism
Center for Innovation and Research Organization

Completed

A Clinical Simulation Study of a Test Material on the Anterior Nares

Colonization, Asymptomatic

United States
Assistance Publique - Hôpitaux de Paris

Completed

Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. (RIPORT)

Deep Vein Thrombosis | Chronic Portal Vein Thrombosis

France
Fadoi Foundation, Italy
University Of Perugia

Completed

Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer. (PRO-LAPSII)

Prevention of Venous Thromboembolism

Italy
Samsung Medical Center
Bayer

Unknown

Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment (XAIENT)

Renal Insufficiency | Atrial Fibrillation | Elderly | Rivaroxaban

Korea, Republic of
Ahmad Tarhini
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Intraocular Melanoma | Malignant Conjunctival Neoplasm | Melanoma (Skin)

United States
Population Health Research Institute
Bayer; University of Cape Town

Completed

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority (INVICTUS-VKA)

Rheumatic Heart Disease

Botswana, Philippines, Zimbabwe, India, China, Egypt, Ethiopia, Uganda, Brazil, South Africa, Cameroon, Tanzania, Kenya, Zambia, Kazakhstan, Kyrgyzstan, Malawi, Mexico, Mozambique, Nepal, Nigeria, Pakistan, Paraguay, Rwanda, Sudan
AtriCure, Inc.

Completed

AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS) (ATLAS)

Post-Operative Atrial Fibrillation

United States

Search clinical trials for: Rivaroxaban, (BAY59-7939)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations